Castration of male piglets without anesthesia causes significant acute pain, behavioral distress, and post-operative discomfort lasting days. The Five Freedoms framework classifies this as a welfare failure. Countries like Norway and the Netherlands have phased out non-anesthetized castration.
Immunocastration uses a vaccine (Improvac) to temporarily suppress testosterone, eliminating boar taint without surgery. Pigs show normal behavior and growth throughout most of their lives. The European Food Safety Authority endorses immunocastration as a welfare-positive alternative.
Breeding programs now identify and select against the gene variants (androstenone, skatole pathways) responsible for boar taint. Genetic progress has been rapid in breeds like Duroc and Yorkshire. This long-term approach eliminates taint without any intervention.
Raising intact males without castration is practiced in some markets with strict sorting and early slaughter. Slaughter before sexual maturity reduces taint occurrence. Consumer acceptance of minor taint varies by market.
Where castration continues, regulations in the EU require local anesthesia (lidocaine) and post-operative analgesics (meloxicam). Research shows these significantly reduce pain scores and behavioral distress. Training stockpeople in proper technique is essential.
The EU Barcelona Declaration set a 2018 target for voluntary elimination of non-anesthetized castration. Progress has been uneven. Full elimination requires economic incentives, alternative uptake, and market alignment across the supply chain.